User login
Key clinical point: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous (SC) injection was noninferior to intravenous (IV) dosing in patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer.
Major finding: Geometric mean ratio of cycle 7 pertuzumab serum Ctrough of the SC group to the IV group was 1.22 (90% confidence interval, 1.14-1.31). Total pathologic complete response was achieved by 59.5% and 59.7% of patients in IV and SC groups, respectively. Common grade 3-4 adverse events were similar.
Study details: In the phase 3 FeDeriCa trial, patients with HER2+ early breast cancer were randomly assigned to receive either fixed-dose SC (n = 248) or IV (n = 252) pertuzumab and trastuzumab along with neoadjuvant chemotherapy.
Disclosures: This study was funded by F Hoffmann-La Roche and Genentech. The lead author AR Tan reported receving financial support from F Hoffmann-La Roche, Genentech, Pfizer, Merck, Tesaro, Novartis, Immunomedics, Celgene, and AbbVie. His coauthors also reported relationships with various pharmaceutical companies including F Hoffmann-La Roche and Genentech.
Source: Tan AR et al. Lancet Oncol. 2020 Dec 21. doi: 10.1016/S1470-2045(20)30536-2.
Key clinical point: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous (SC) injection was noninferior to intravenous (IV) dosing in patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer.
Major finding: Geometric mean ratio of cycle 7 pertuzumab serum Ctrough of the SC group to the IV group was 1.22 (90% confidence interval, 1.14-1.31). Total pathologic complete response was achieved by 59.5% and 59.7% of patients in IV and SC groups, respectively. Common grade 3-4 adverse events were similar.
Study details: In the phase 3 FeDeriCa trial, patients with HER2+ early breast cancer were randomly assigned to receive either fixed-dose SC (n = 248) or IV (n = 252) pertuzumab and trastuzumab along with neoadjuvant chemotherapy.
Disclosures: This study was funded by F Hoffmann-La Roche and Genentech. The lead author AR Tan reported receving financial support from F Hoffmann-La Roche, Genentech, Pfizer, Merck, Tesaro, Novartis, Immunomedics, Celgene, and AbbVie. His coauthors also reported relationships with various pharmaceutical companies including F Hoffmann-La Roche and Genentech.
Source: Tan AR et al. Lancet Oncol. 2020 Dec 21. doi: 10.1016/S1470-2045(20)30536-2.
Key clinical point: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous (SC) injection was noninferior to intravenous (IV) dosing in patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer.
Major finding: Geometric mean ratio of cycle 7 pertuzumab serum Ctrough of the SC group to the IV group was 1.22 (90% confidence interval, 1.14-1.31). Total pathologic complete response was achieved by 59.5% and 59.7% of patients in IV and SC groups, respectively. Common grade 3-4 adverse events were similar.
Study details: In the phase 3 FeDeriCa trial, patients with HER2+ early breast cancer were randomly assigned to receive either fixed-dose SC (n = 248) or IV (n = 252) pertuzumab and trastuzumab along with neoadjuvant chemotherapy.
Disclosures: This study was funded by F Hoffmann-La Roche and Genentech. The lead author AR Tan reported receving financial support from F Hoffmann-La Roche, Genentech, Pfizer, Merck, Tesaro, Novartis, Immunomedics, Celgene, and AbbVie. His coauthors also reported relationships with various pharmaceutical companies including F Hoffmann-La Roche and Genentech.
Source: Tan AR et al. Lancet Oncol. 2020 Dec 21. doi: 10.1016/S1470-2045(20)30536-2.